Maintaining versus Switching Antiviral Therapy in Chronic Hepatitis B Patients with Low-level Viremia

CHB patients were enrolled in the hepatitis clinic of West China Hospital of Sichuan University from November 2020 to November 2023. Enrollment criteria were: (1) Receive monotherapy with ETV, TDF, and TAF for at least 48 weeks; (2) Conventional HBV DNA testing below LLOQ (LLOQ: 100 IU/ml); (3) Voluntary participation in high-sensitivity HBV DNA testing(LLOQ: 10 IU/ml).

Exclusion criteria were : (1) Treatment with IFN-α or non-first-line antiviral drugs within 12 months before enrollment; (2) Combination therapy with other antiviral drugs such as NAs+NAs and NAs+IFN-α within 12 months before enrollment; (3) Combining drug-induced, hereditary, alcoholic, autoimmune, metabolic and other liver diseases; (4) History of liver tumors or other malignant tumors; (5) Accept immunosuppressive drugs, cytotoxic drugs, and radiotherapy and chemotherapy treatment; (6) Patients with poor compliance or self-withdrawal during follow-up.